InvestSMART

Clarity Pharmaceuticals Ltd (ASX:CU6)

ALERT: Price-sensitive ASX Announcement for CU6
Current share price for CU6 : $2.360 0.545 (30.03%)+
Announcement
Release
29 Jun 2026 9:56AM
Price at Release
$1.815
Full Release
download
Summary
Clarity Pharmaceuticals Ltd presented data on their product 67Cu-SAR-bisPSMA at the EANM 2026 Annual Congress, showcasing its potential in treating metastatic castration-resistant prostate cancer (mCRPC). The presentation detailed case studies from their Phase I/IIa SECuRE trial where patients experienced significant declines in prostate-specific antigen (PSA) levels and undetectable disease after treatment. 67Cu-SAR-bisPSMA demonstrated strong anti-tumor activity with manageable adverse effects. Additionally, the product 64Cu-SAR-bisPSMA was highlighted for its improved diagnostic performance over standard imaging techniques, emphasizing Clarity’s commitment to enhancing prostate cancer diagnosis and treatment through innovative radiopharmaceuticals.
Key Points
  • 67Cu-SAR-bisPSMA showcased at EANM 2026 Annual Congress.
  • Case study of two participants from Clarity’s Phase I/IIa SECuRE trial presented.
  • Participant A experienced a 95.7% decline in PSA levels and undetectable disease after four cycles of treatment.
  • Participant B showed a 94.2% decline in PSA levels and complete response on imaging after two cycles.
  • 64Cu-SAR-bisPSMA improves diagnostic performance over standard SOC imaging.
  • Clarity Pharmaceuticals focuses on advancing SAR-bisPSMA for prostate cancer diagnosis and treatment.
  • SAR-bisPSMA technology utilizes copper isotopes for targeted theranostics.
  • Presentations available on Clarity’s official website post-EANM 2026 Congress.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.